Cpg-Methylation-Based Risk Score Predicts Progression in Colorectal Cancer

作者：Yao Deng, Hao Wan, Jianbo Tian, Xiang Cheng, Meilin Rao, Jiaoyuan Li, Hongli Zhang, Ming Zhang, Yimin Cai, Zequn Lu, Yue Li, Siyuan Niu, Na Shen, Jiang Chang, Zemin Fang, Rong Zhong · 发表于：Epigenomics · 年份：2020 · DOI：10.2217/epi-2019-0300 · 被引用次数：21 · 研究领域：Genetic factors in colorectal cancer、Epigenetics and DNA Methylation、Cancer-related molecular mechanisms research

Aim: To identify patients with colorectal cancer (CRC) who are at a truly higher risk of progression, which is key for individualized approaches to precision therapy. Materials & methods: We developed a predictor associated with progression-free interval (PFI) using The Cancer Genome Atlas CRC methylation data. Results: The risk score was associated with PFI in the whole cohort (p < 0.001). A nomogram consisting of the risk score and other significant clinical features was generated to predict the 3- and 5-year PFI in the whole set (area under the curve: 0.79 and 0.71, respectively). Conclusion: The risk score based on 23 DNA-methylation sites may serve as the basis for improved prediction of progression in patients with CRC in future clinical practice.